ArticleFuture oncology (London, England)2024

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR

Elena Elez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.